The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.

August 12, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limit Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001. Mumbai – 400051 Ref:- Scrip ID:- 500126 Ref:- Scrip Code:- PGHL Dear Sir / Madam, Sub: Business Responsibility & Sustainability Report for the Financial Year ended March 31, 2026 Please find enclosed herewith the Business Responsibility & Sustainability Report for the Financial Year ended March 31, 2026 which forms a part of the Annual Report for the Financial Year ended March 31, 2026. Kindly take the same on record and oblige. Thanking you, Yours faithfully, For Procter & Gamble Health Limited Flavia Machado Authorized Signatory Procter & Gamble Health Limited ANNEXURE I BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT 2025-26 Milind Thatte Managing Director 18 Annual Report 2025-26 Annual Report 2025-26 19 Company Overview Director's Report Corporate Governance Financial Statements Procter & Gamble Health Limited SECTION A: GENERAL DISCLOSURES I. Details of the listed entity Sr. No. Particulars Details 3. 1967 together) II. Products/services 16. Details of business activities (accounting for 90% of the turnover): Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. 100% 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Sr. No. Product/Service NIC Code % of total Turnover contributed 1. 100% III. Operations Location Number of plants Total National 1 23* 24 International - - - Procter & Gamble Health Limited 19. Markets served by the entity: a. Number of locations Locations Number * During the Financial Year 2025-26, the Company exported products to 5 countries. b. What is the contribution of exports 8.24% c. A brief on types of customers inter alia IV. Employees 20. Details as at the end of Financial Year: Sr. Particulars Total Male Female No. (A) No. (B) % (B / A) No. (C) % (C / A) Employees (other than workers) 1. 221 161 73 60 27 2. - - - - - 3. Total employees (D + E) 221 161 73 60 27 Workers 4. 1055 953 90 102 10 5. 224 155 69 69 31 6. Total workers (F + G) 1279 1108 87 171 13 * Other than permanent workers include contractual labour. 21. Participation/Inclusion/Representation of women: Sr. No. Designation Total (A) No. and percentage of females No. (B) % (B/A) 1. Board of Directors 7 2 28.57 2. Key Managerial Personnel 3* 1 33.33 * 2 KMPs, viz., Mr. Milind Thatte, Managing Director and Mr. Shashank Srowthy, Executive Director and CFO are also part of the Board of Directors. 22. Turnover rate for permanent employees and workers F.Y. 2025-26 F.Y. 2024-25 F.Y. 2023-24 Male Female Total Male Female Total Male Female Total 7.50% 1.70% 5.90% 4.41% 5.20% 4.98% 17.72% 26.44% 18.73% 8.20% 10.80% 8.40% 11.61% 8.04% 8.38% 40.64% 51.69% 41.90% 20 Annual Report 2025-26 Annual Report 2025-26 21 Company Overview Director's Report Corporate Governance Financial Statements Procter & Gamble Health Limited V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures Sr. Name of the holding / Indicate % of shares Does the entity indicated at column A, No. subsidiary / associate whether holding held participate in the Business Responsibility companies / joint / Subsidiary initiatives of the listed entity? (Yes/No) ventures (A) / Associate / Joint Venture 1. 52.18% (Indirect through its subsidiary) 2. 52.18% (Direct shareholding) VI. CSR Details 24. (i) Whether CSR is applicable as per Section 135 of Companies Act, 2013: (ii) Turnover: (iii) Net worth: VII. Transparency and Disclosures Compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Stakeholder Grievance Redressal F.Y. 2025-26 F.Y. 2024-25 group from Mechanism in Place (Yes/ Number of Number of Remarks Number of Number of Remarks whom No) (If Yes, then provide complaints complaints complaints complaints complaint is web-link for grievance pending pending received redress policy) the year resolution during the resolution at at close of year close of the the year year 40 1 - 33 1 - 4 - 7 - (other than 3 - 5 - Procter & Gamble Health Limited 26. Overview of the entity’s material responsible business conduct issues: Note: Information provided in this report, including in response to this item, should not be construed as “material” for purposes Indian Companies Act, 2013 (read with Rules thereunder), U.S. securities laws and regulations, or the laws or regulations of any jurisdiction. We provide information below on the environmental and social matters that we judge to be most relevant and meaningful to our business. Sr. Material Indicate Rationale for In case of risk, approach to Financial implications of the risk No. issue whether risk identifying the risk / adapt or mitigate or opportunity (Indicate positive or or opportunity opportunity negative implications) (R/O) 22 Annual Report 2025-26 Annual Report 2025-26 23 Company Overview Director's Report Corporate Governance Financial Statements Procter & Gamble Health Limited SECTION B: MANAGEMENT AND PROCESS DISCLOSURES This section is aimed at helping businesses demonstrate the structures, policies and processes put in place Sr. Questions P1 P2 P3 P4 P5 P6 P7 P8 P9 Policy and management processes 1. a. Governance, leadership and oversight Procter & Gamble Health Limited Sr. Questions P1 P2 P3 P4 P5 P6 P7 P8 P9 10. If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE PRINCIPLE 1- Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable 24 Annual Report 2025-26 Annual Report 2025-26 25 Company Overview Director's Report Corporate Governance Financial Statements Procter & Gamble Health Limited 1. Percentage coverage by training and awareness programmes on any of the Principles during the Segment Total number of Topics / principles covered under the % of persons in training / awareness training / awareness programs respective category programmes held covered by the awareness programmes 5* 100% 5** 100% Training * Various topics discussed at Board & Committee meetings, and other connects held from time to time. ** Above cover the system-monitored mandatory web-based trainings deployed to employees. Apart from the above, there are various other virtual and in-person trainings conducted from time-to-time to relevant employees, based on functions, new-joiners etc. on various topics such as Worldwide Business Conduct Manual, Prevention of Sexual Harassment, Data Privacy, Anti-bribery etc. (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, the entity’s website) 3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed - 4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy. Procter & Gamble Health Limited 5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption: F.Y. 2025-26 F.Y. 2024-25 F.Y. 2025-26 F.Y. 2024-25 Number Remark Number Remark of interest- 8. Number of days of accounts payables [Accounts payable *365) / Cost of goods/services procured]: F.Y. 2025-26 F.Y. 2024-25 192 239 9. Open-ness of business Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties: Pa [Showing first 8,000 characters — download PDF for full document]